论文部分内容阅读
目的对比分析诊断模型(LIF-5、APRI及FIB-4)对丙氨酸转移酶(ALT)<2×正常值上限(ULN)慢性乙型肝炎病毒(HBV)感染者治疗指征(≥G2或≥S2)的判断价值。方法收集1 135例接受肝脏穿刺活检术患者的临床资料,分为0.75时,特异度97.3%、阳性预测值87.1%。结论有较高比例的ALT<2×ULN慢性HBV感染者存在明显肝脏疾病进展,诊断模型LIF-5对治疗指征的判断有较好的价值,值得推广。
OBJECTIVE: To compare the diagnostic value of LIF-5, APRI and FIB-4 in the treatment of patients with chronic hepatitis B virus (HBV) infection with ALT <2 × upper limit of normal (ULN) Or ≧ S2). Methods The clinical data of 1 135 patients who underwent liver biopsy were collected and divided into group G2 and group S2, group G2 or group S2, and the diagnostic model LIF-5 was constructed to evaluate the effect of LIF-5, APRI and FIB-4 treatment Indications to determine the value. Results ≥G2 or ≥ S2 group of patients accounted for 44.49%; the group of male and HBeAg negative composition, age, ALT, AST, APRI and FIB-4 average were higher than 0.75, the specificity was 97.3% and the positive predictive value was 87.1%. Conclusions There is a significant proportion of patients with chronic HBV infection with ALT <2 × ULN. The diagnosis of LIF-5 is of great value in judging indications for treatment, which is worthy of promotion.